We invest in growth stage diagnostic companies and empower them with the full strength of our collective resources, capital, and expertise.
Biocrucible aims to develop proprietary molecular detection technologies deploying ultra-rapid isothermal nucleic acid amplification that enable near patient and at-home testing for infectious disease or generic indications.
Our mission is to help consumers access important diagnostic results in a simple way. We deliver the true potential of healthcare diagnostics directly to you by curating a broad portfolio of products, from rapid home tests to advanced laboratory testing services.
GrapheneDx is designing a device that will put the power of the highest performing diagnostics in the palm of your hand and the comfort of your home. Our platform technology will enable better and faster health management anywhere, anytime.
Sapphiros AI Bio is a computational biology company developing high-performance computing, machine learning, and artificial intelligence solutions for biochemistry, cell biology, and diagnostics. Our mission is to impact health care by developing deep understanding of human biology and disease.
Sapphiros Laboratories is a leading provider of genetic and COVID-19 testing. Our national scale and comprehensive clinical and digital solutions enable us to provide a seamless collection, testing and reporting solution.
The SatioPatch™ Platform provides consumer-based diagnosis through a convenient and simple to use patch utilizing a wide variety of technologies for an increasing demand for rapid, point of care diagnosis.